Hera Biotech is on a mission to transform women’s health with non-invasive, non-surgical solutions for conditions that have long been underdiagnosed or misunderstood, beginning with endometriosis and cervical cancer.
Launching with three full-time employees, Hera Biotech scaled to twelve contributors in one year, blending full-time and contractor roles. To accelerate progress, the team turned to MDisrupt, where they secured a computational biologist with rare expertise in single-cell and bulk assay design. This engagement became a turning point, helping the company validate complex data, generate new intellectual property, and advance the company’s diagnostic platform.
As Hera Biotech prepared to move from early-stage research to clinical translation, the team faced two critical obstacles:
“We needed someone who could not only handle the science but explain it clearly and help us make real progress. That’s when we found Neil through MDisrupt.”
— Somer Baburek, CEO, Hera Biotech
MDisrupt connected Hera Biotech with a computational biologist who quickly became a trusted team member, delivering structured outputs and anticipating both scientific and investor needs. With this expertise, Hera:
Hera Biotech’s experience using expert talent to solve go-to-market challenges illustrates how pairing deep domain expertise with early-stage innovation can dramatically shift timelines and outcomes. Partnering with MDisrupt enabled the company to clear technical hurdles, accelerate clinical readiness, and lay the foundation for continued innovation in women’s health diagnostics.
